Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties
Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor...
Saved in:
Published in | NPJ systems biology and applications Vol. 10; no. 1; pp. 20 - 13 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
21.02.2024
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor microenvironment (TME) plays an important role in the development and progression of PCa. In addition to tumor cells, TME-resident macrophages and fibroblasts express AR and are therefore also affected by ADT. However, the interplay of different TME cell types in the development of CRPC remains largely unexplored. To understand the complex stochastic nature of cell-cell interactions, we created a PCa-specific agent-based model (PCABM) based on in vitro cell proliferation data. PCa cells, fibroblasts, “pro-inflammatory” M1-like and “pro-tumor” M2-like polarized macrophages are modeled as agents from a simple set of validated base assumptions. PCABM allows us to simulate the effect of ADT on the interplay between various prostate TME cell types. The resulting in vitro growth patterns mimic human PCa. Our PCABM can effectively model hormonal perturbations by ADT, in which PCABM suggests that CRPC arises in clusters of resistant cells, as is observed in multifocal PCa. In addition, fibroblasts compete for cellular space in the TME while simultaneously creating niches for tumor cells to proliferate in. Finally, PCABM predicts that ADT has immunomodulatory effects on macrophages that may enhance tumor survival. Taken together, these results suggest that AR plays a critical role in the cellular interplay and stochastic interactions in the TME that influence tumor cell behavior and CRPC development. |
---|---|
AbstractList | Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor microenvironment (TME) plays an important role in the development and progression of PCa. In addition to tumor cells, TME-resident macrophages and fibroblasts express AR and are therefore also affected by ADT. However, the interplay of different TME cell types in the development of CRPC remains largely unexplored. To understand the complex stochastic nature of cell-cell interactions, we created a PCa-specific agent-based model (PCABM) based on in vitro cell proliferation data. PCa cells, fibroblasts, “pro-inflammatory” M1-like and “pro-tumor” M2-like polarized macrophages are modeled as agents from a simple set of validated base assumptions. PCABM allows us to simulate the effect of ADT on the interplay between various prostate TME cell types. The resulting in vitro growth patterns mimic human PCa. Our PCABM can effectively model hormonal perturbations by ADT, in which PCABM suggests that CRPC arises in clusters of resistant cells, as is observed in multifocal PCa. In addition, fibroblasts compete for cellular space in the TME while simultaneously creating niches for tumor cells to proliferate in. Finally, PCABM predicts that ADT has immunomodulatory effects on macrophages that may enhance tumor survival. Taken together, these results suggest that AR plays a critical role in the cellular interplay and stochastic interactions in the TME that influence tumor cell behavior and CRPC development. Abstract Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor microenvironment (TME) plays an important role in the development and progression of PCa. In addition to tumor cells, TME-resident macrophages and fibroblasts express AR and are therefore also affected by ADT. However, the interplay of different TME cell types in the development of CRPC remains largely unexplored. To understand the complex stochastic nature of cell-cell interactions, we created a PCa-specific agent-based model (PCABM) based on in vitro cell proliferation data. PCa cells, fibroblasts, “pro-inflammatory” M1-like and “pro-tumor” M2-like polarized macrophages are modeled as agents from a simple set of validated base assumptions. PCABM allows us to simulate the effect of ADT on the interplay between various prostate TME cell types. The resulting in vitro growth patterns mimic human PCa. Our PCABM can effectively model hormonal perturbations by ADT, in which PCABM suggests that CRPC arises in clusters of resistant cells, as is observed in multifocal PCa. In addition, fibroblasts compete for cellular space in the TME while simultaneously creating niches for tumor cells to proliferate in. Finally, PCABM predicts that ADT has immunomodulatory effects on macrophages that may enhance tumor survival. Taken together, these results suggest that AR plays a critical role in the cellular interplay and stochastic interactions in the TME that influence tumor cell behavior and CRPC development. Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor microenvironment (TME) plays an important role in the development and progression of PCa. In addition to tumor cells, TME-resident macrophages and fibroblasts express AR and are therefore also affected by ADT. However, the interplay of different TME cell types in the development of CRPC remains largely unexplored. To understand the complex stochastic nature of cell-cell interactions, we created a PCa-specific agent-based model (PCABM) based on in vitro cell proliferation data. PCa cells, fibroblasts, "pro-inflammatory" M1-like and "pro-tumor" M2-like polarized macrophages are modeled as agents from a simple set of validated base assumptions. PCABM allows us to simulate the effect of ADT on the interplay between various prostate TME cell types. The resulting in vitro growth patterns mimic human PCa. Our PCABM can effectively model hormonal perturbations by ADT, in which PCABM suggests that CRPC arises in clusters of resistant cells, as is observed in multifocal PCa. In addition, fibroblasts compete for cellular space in the TME while simultaneously creating niches for tumor cells to proliferate in. Finally, PCABM predicts that ADT has immunomodulatory effects on macrophages that may enhance tumor survival. Taken together, these results suggest that AR plays a critical role in the cellular interplay and stochastic interactions in the TME that influence tumor cell behavior and CRPC development.Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor microenvironment (TME) plays an important role in the development and progression of PCa. In addition to tumor cells, TME-resident macrophages and fibroblasts express AR and are therefore also affected by ADT. However, the interplay of different TME cell types in the development of CRPC remains largely unexplored. To understand the complex stochastic nature of cell-cell interactions, we created a PCa-specific agent-based model (PCABM) based on in vitro cell proliferation data. PCa cells, fibroblasts, "pro-inflammatory" M1-like and "pro-tumor" M2-like polarized macrophages are modeled as agents from a simple set of validated base assumptions. PCABM allows us to simulate the effect of ADT on the interplay between various prostate TME cell types. The resulting in vitro growth patterns mimic human PCa. Our PCABM can effectively model hormonal perturbations by ADT, in which PCABM suggests that CRPC arises in clusters of resistant cells, as is observed in multifocal PCa. In addition, fibroblasts compete for cellular space in the TME while simultaneously creating niches for tumor cells to proliferate in. Finally, PCABM predicts that ADT has immunomodulatory effects on macrophages that may enhance tumor survival. Taken together, these results suggest that AR plays a critical role in the cellular interplay and stochastic interactions in the TME that influence tumor cell behavior and CRPC development. |
ArticleNumber | 20 |
Author | Zaalberg, Anniek Bergman, Andries M. Zwart, Wilbert van Genderen, Maisa N. G. Bekers, Elise M. Eduati, Federica Kneppers, Jeroen |
Author_xml | – sequence: 1 givenname: Maisa N. G. orcidid: 0000-0002-7394-9888 surname: van Genderen fullname: van Genderen, Maisa N. G. organization: Department of Biomedical Engineering, Eindhoven University of Technology, PO Box 513, Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121 – sequence: 2 givenname: Jeroen surname: Kneppers fullname: Kneppers, Jeroen organization: Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121 – sequence: 3 givenname: Anniek surname: Zaalberg fullname: Zaalberg, Anniek organization: Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121 – sequence: 4 givenname: Elise M. surname: Bekers fullname: Bekers, Elise M. organization: Division of Pathology, Netherlands Cancer Institute, Plesmanlaan 121 – sequence: 5 givenname: Andries M. orcidid: 0000-0001-5223-2549 surname: Bergman fullname: Bergman, Andries M. email: a.bergman@nki.nl organization: Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, Division of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121 – sequence: 6 givenname: Wilbert orcidid: 0000-0002-9823-7289 surname: Zwart fullname: Zwart, Wilbert email: w.zwart@nki.nl organization: Department of Biomedical Engineering, Eindhoven University of Technology, PO Box 513, Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513 – sequence: 7 givenname: Federica orcidid: 0000-0002-7822-3867 surname: Eduati fullname: Eduati, Federica email: f.eduati@tue.nl organization: Department of Biomedical Engineering, Eindhoven University of Technology, PO Box 513, Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513 |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38383542$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Ustu1DAUjVARfdAfYIEisWET8DueFaoqHpUqsYG15dg3GY8Se7CdqfoB_DdOZ1raLiovbNnnnHt87zmtjnzwUFXvMPqEEZWfE8OcoQYR1iBEGWvEq-qEIC6aFsvV0aPzcXWe0gYhhAVlBKM31TGVZXFGTqq_FwP43HQ6ga2nYGF0fqhDX-c11NsYUtYZ6jxPIdaTMzGA37kY_FRY9exN2EFMddrq7PR4wA0x3OR1bYJPOWrnc6q1t7WbptmHUmMedQ7xdpHfQswO0tvqda_HBOeH_az6_e3rr8sfzfXP71eXF9eN4QznBrCWHRE9J53tWtGBRZQLZo3kvOMdQcjotheyRUSAkCtGgbTCMGwpRiu7omfV1V7XBr1R2-gmHW9V0E7dXYQ4KF0MmRGUMRaRlsm2J4ZJoFpgi0nHkJSs58CK1pe91nbuJrCmNCTq8Yno0xfv1moIO4WLBOZEFoWPB4UY_syQsppcMjCO2kOYkyIrilhbZrtAPzyDbsIcfelVQS042bLF0vvHlh683I-7AMgeUAaZUoT-AYKRWmKl9rFSJVbqLlZKFJJ8RjKupMKF5VtufJlK99RU6vgB4n_bL7D-AXSD5GU |
CitedBy_id | crossref_primary_10_3389_fphys_2024_1473125 crossref_primary_10_1016_j_jtbi_2025_112048 crossref_primary_10_3389_fphys_2024_1491144 |
Cites_doi | 10.1080/2162402X.2018.1462431 10.1053/j.seminoncol.2014.03.004 10.1177/0037549717699072 10.1158/1078-0432.CCR-06-0067 10.1002/pros.23742 10.1016/j.ces.2007.11.024 10.1016/j.ccell.2020.06.005 10.1016/j.matcom.2016.05.008 10.1158/0008-5472.CAN-17-2006 10.1038/bjc.2011.385 10.1007/7651_2016_346 10.1038/s41388-018-0583-7 10.1016/j.lfs.2019.116791 10.1007/s00262-007-0343-y 10.3322/caac.21660 10.1038/nrc3245 10.1186/s12943-019-0976-4 10.1371/journal.pone.0047045 10.1530/ERC-18-0042 10.1189/jlb.0609385 10.1371/journal.pcbi.1004025 10.3389/fimmu.2020.519383 10.1111/j.1742-1241.2011.02799.x 10.1038/s41467-020-18313-y 10.1073/pnas.1115750108 10.1038/bjc.2013.748 10.1158/1541-7786.MCR-20-0740 10.1158/0008-5472.CAN-12-3228 10.1016/j.ccell.2021.09.005 10.1002/cbin.11528 10.1155/2022/8580043 10.1158/1078-0432.CCR-18-0461 10.1371/journal.pone.0122827 10.1158/2767-9764.CRC-23-0097 10.1111/j.1464-410X.2010.09804.x 10.1073/pnas.1815735116 10.1016/j.jtbi.2010.02.027 10.1063/1.3697848 10.1016/j.tcb.2022.10.006 10.1088/1478-3975/9/1/016002 10.1186/1475-2867-5-8 10.1158/0008-5472.CAN-18-1126 10.1016/j.semcancer.2008.03.004 10.1016/j.humpath.2010.02.011 10.7554/eLife.76284 10.1002/1878-0261.12327 10.1210/er.2002-0032 10.1371/journal.pone.0060562 10.3390/cancers14194923 10.1038/onc.2013.191 10.1016/j.cell.2018.11.021 10.1002/pros.20927 10.4049/jimmunol.1800352 10.1200/JCO.2002.10.018 10.1038/s41388-019-0805-7 10.1038/s41467-022-33780-1 10.1007/s00332-008-9031-0 10.1200/CCI.18.00057 10.1080/10446670310001626580 10.1101/2023.06.06.543873 |
ContentType | Journal Article |
Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1038/s41540-024-00344-6 |
DatabaseName | Springer Nature OA/Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central (ProQuest) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2056-7189 |
EndPage | 13 |
ExternalDocumentID | oai_doaj_org_article_ccd027487f2c48e3a61d12b40884f5e4 PMC10881528 38383542 10_1038_s41540_024_00344_6 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Oncode Institute |
GroupedDBID | 0R~ 5VS 7X7 8FE 8FH 8FI AAJSJ AASML ABUWG ACGFS ADBBV AFKRA ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C EBLON EBS FYUFA GROUPED_DOAJ HCIFZ HYE KQ8 LK8 M7P M~E NAO NO~ OK1 PGMZT PIMPY PQQKQ PROAC PUEGO RNT RPM SNYQT UKHRP 8FJ AAYXX CCPQU CITATION HMCUK PHGZM PHGZT CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AARCD AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQGLB PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c541t-e1a8b26f52bdb76bed03564dc855b5b200ca7f687026e68943e276c41d3109d93 |
IEDL.DBID | 7X7 |
ISSN | 2056-7189 |
IngestDate | Wed Aug 27 01:30:39 EDT 2025 Thu Aug 21 18:35:22 EDT 2025 Thu Jul 10 22:44:32 EDT 2025 Wed Aug 13 03:26:52 EDT 2025 Mon Jul 21 05:50:35 EDT 2025 Thu Apr 24 22:58:06 EDT 2025 Tue Jul 01 01:18:36 EDT 2025 Sun Aug 31 08:58:36 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c541t-e1a8b26f52bdb76bed03564dc855b5b200ca7f687026e68943e276c41d3109d93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-7394-9888 0000-0002-7822-3867 0000-0002-9823-7289 0000-0001-5223-2549 |
OpenAccessLink | https://www.proquest.com/docview/2929308744?pq-origsite=%requestingapplication% |
PMID | 38383542 |
PQID | 2929308744 |
PQPubID | 2041915 |
PageCount | 13 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_ccd027487f2c48e3a61d12b40884f5e4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10881528 proquest_miscellaneous_2930473448 proquest_journals_2929308744 pubmed_primary_38383542 crossref_primary_10_1038_s41540_024_00344_6 crossref_citationtrail_10_1038_s41540_024_00344_6 springer_journals_10_1038_s41540_024_00344_6 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-02-21 |
PublicationDateYYYYMMDD | 2024-02-21 |
PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-21 day: 21 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | NPJ systems biology and applications |
PublicationTitleAbbrev | npj Syst Biol Appl |
PublicationTitleAlternate | NPJ Syst Biol Appl |
PublicationYear | 2024 |
Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
References | Kather (CR46) 2017; 77 Poleszczuk, Macklin, Enderling (CR42) 2016; 1516 Cioni (CR30) 2020; 11 Poleszczuk, Hahnfeldt, Enderling (CR41) 2015; 11 Kirby, Hirst, Crawford (CR57) 2011; 65 Becerra-Díaz, Strickland, Keselman, Heller (CR31) 2018; 201 Olumi (CR12) 1999; 59 Zhang (CR18) 2020; 38 Erlandsson (CR50) 2019; 79 Frascoli, Flood, Kim (CR43) 2017; 34 He (CR63) 2019; 38 Henshall (CR25) 2001; 61 Fang (CR27) 2013; 73 Ideta, Tanaka, Takeuchi, Aihara (CR37) 2008; 18 Heinlein, Chang (CR3) 2004; 25 Kfoury (CR15) 2021; 39 Tanaka, Hirata, Goldenberg, Bruchovsky, Aihara (CR38) 2010; 368 Chiarugi, Paoli, Cirri (CR62) 2014; 41 Zhang, Cunningham, Brown, Gatenby (CR34) 2022; 11 Portz, Kuang, Nagy (CR36) 2012; 2 Ab Wahab, Nefti-Meziani, Atyabi (CR66) 2015; 10 Enot, Vacchelli, Jacquelot, Zitvogel, Kroemer (CR69) 2018; 7 Payne, Mason (CR56) 2011; 105 Lissbrant (CR28) 2000; 17 Ayala (CR60) 2003; 9 Yang, Fung, Day, Kropp, Lin (CR4) 2005; 5 Cioni, Zwart, Bergman (CR22) 2018; 25 Andreoiu, Cheng (CR58) 2010; 41 Comito (CR49) 2014; 33 Sung (CR1) 2021; 71 Rohrs, Wang, Finley (CR29) 2019; 3 West, Robertson-Tessi, Anderson (CR40) 2023; 33 CR59 Geldhof, van Ginderachter, Liu, Noël, de Baetselier (CR53) 2003; 10 Hirata, Bruchovsky, Aihara (CR35) 2010; 264 Sun, Wu, He, He, Sun (CR20) 2019; 235 Wikström, Marusic, Stattin, Bergh (CR8) 2009; 69 Nagasaki (CR16) 2014; 110 Pourhasanzade, Sabzpoushan, Alizadeh, Esmati (CR44) 2017; 93 Passier (CR48) 2023; 3 Kather (CR47) 2018; 78 Jalalimanesh, Haghighi, Ahmadi, Soltani (CR45) 2017; 133 Consiglio, Gollnick (CR32) 2020; 11 Neal (CR14) 2018; 175 Edin (CR23) 2012; 7 Siefert (CR24) 2021; 19 Singer (CR61) 2013; 8 Lorenzo, Hughes, Dominguez-Frojan, Reali, Gomez (CR33) 2019; 116 Han (CR52) 2022; 2022 Wong (CR11) 2022; 13 Solinas, Germano, Mantovani, Allavena (CR54) 2009; 86 Schwaab, Biscaia, Monteiro, Pinto (CR67) 2008; 63 Cioni (CR26) 2018; 12 Sica (CR21) 2008; 18 Pienta, Bradley (CR5) 2006; 12 Wei (CR55) 2019; 18 Kumar (CR10) 2022; 14 Nonomura (CR13) 2011; 107 Tu, Dou, Wang, Zhuang, Zhang (CR51) 2021; 45 Gelmann (CR2) 2002; 20 Olapade-Olaopa (CR7) 1999; 5 Tan, Bora (CR68) 2017; 11 Ippolito (CR19) 2019; 38 CR65 Lazar (CR64) 2012; 9 Jain, Clinton, Bhinder, Friedman (CR39) 2011; 108 Huang (CR9) 2018; 24 Croci (CR17) 2007; 56 Fridman, Pagès, Sautès-Fridman, Galon (CR6) 2012; 12 H Sung (344_CR1) 2021; 71 AM Ideta (344_CR37) 2008; 18 A Jalalimanesh (344_CR45) 2017; 133 V Kumar (344_CR10) 2022; 14 B Cioni (344_CR30) 2020; 11 N Nonomura (344_CR13) 2011; 107 E Singer (344_CR61) 2013; 8 344_CR65 AF Olumi (344_CR12) 1999; 59 Z Zhang (344_CR18) 2020; 38 DC Lazar (344_CR64) 2012; 9 M Becerra-Díaz (344_CR31) 2018; 201 P Chiarugi (344_CR62) 2014; 41 L-Y Fang (344_CR27) 2013; 73 H Payne (344_CR56) 2011; 105 L Ippolito (344_CR19) 2019; 38 DO Croci (344_CR17) 2007; 56 J Poleszczuk (344_CR42) 2016; 1516 F Frascoli (344_CR43) 2017; 34 AB Geldhof (344_CR53) 2003; 10 P Wikström (344_CR8) 2009; 69 T Portz (344_CR36) 2012; 2 M Kirby (344_CR57) 2011; 65 Q Yang (344_CR4) 2005; 5 B Cioni (344_CR22) 2018; 25 HY Wong (344_CR11) 2022; 13 344_CR59 KJ Pienta (344_CR5) 2006; 12 G Tanaka (344_CR38) 2010; 368 M Andreoiu (344_CR58) 2010; 41 T Nagasaki (344_CR16) 2014; 110 JN Kather (344_CR46) 2017; 77 JA Rohrs (344_CR29) 2019; 3 HV Jain (344_CR39) 2011; 108 WH Fridman (344_CR6) 2012; 12 S Edin (344_CR23) 2012; 7 C Wei (344_CR55) 2019; 18 G Lorenzo (344_CR33) 2019; 116 JN Kather (344_CR47) 2018; 78 CR Consiglio (344_CR32) 2020; 11 DP Enot (344_CR69) 2018; 7 CA Heinlein (344_CR3) 2004; 25 D-Y Sun (344_CR20) 2019; 235 B Cioni (344_CR26) 2018; 12 IF Lissbrant (344_CR28) 2000; 17 F Pourhasanzade (344_CR44) 2017; 93 Y Hirata (344_CR35) 2010; 264 EO Olapade-Olaopa (344_CR7) 1999; 5 H Huang (344_CR9) 2018; 24 A Sica (344_CR21) 2008; 18 G Ayala (344_CR60) 2003; 9 Y He (344_CR63) 2019; 38 J West (344_CR40) 2023; 33 Y Kfoury (344_CR15) 2021; 39 G Comito (344_CR49) 2014; 33 J Zhang (344_CR34) 2022; 11 G Solinas (344_CR54) 2009; 86 RK Tan (344_CR68) 2017; 11 SM Henshall (344_CR25) 2001; 61 M Passier (344_CR48) 2023; 3 MN Ab Wahab (344_CR66) 2015; 10 D Tu (344_CR51) 2021; 45 EP Gelmann (344_CR2) 2002; 20 J Poleszczuk (344_CR41) 2015; 11 M Schwaab (344_CR67) 2008; 63 C Han (344_CR52) 2022; 2022 JC Siefert (344_CR24) 2021; 19 JT Neal (344_CR14) 2018; 175 A Erlandsson (344_CR50) 2019; 79 |
References_xml | – volume: 7 start-page: e1462431 year: 2018 ident: CR69 article-title: TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1462431 – volume: 41 start-page: 267 year: 2014 end-page: 280 ident: CR62 article-title: Tumor microenvironment and metabolism in prostate cancer publication-title: Semin. Oncol. doi: 10.1053/j.seminoncol.2014.03.004 – volume: 93 start-page: 641 year: 2017 end-page: 657 ident: CR44 article-title: An agent-based model of avascular tumor growth: Immune response tendency to prevent cancer development publication-title: Simulation doi: 10.1177/0037549717699072 – volume: 17 start-page: 445 year: 2000 end-page: 451 ident: CR28 article-title: Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival publication-title: Int. J. Oncol. – volume: 368 start-page: 5029 year: 2010 end-page: 5044 ident: CR38 article-title: Mathematical modelling of prostate cancer growth and its application to hormone therapy. publication-title: Phys. Eng. Sci. – volume: 12 start-page: 1665 year: 2006 end-page: 1671 ident: CR5 article-title: Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-0067 – volume: 79 start-page: 363 year: 2019 end-page: 369 ident: CR50 article-title: M2 macrophages and regulatory T cells in lethal prostate cancer publication-title: The Prostate doi: 10.1002/pros.23742 – volume: 63 start-page: 1542 year: 2008 end-page: 1552 ident: CR67 article-title: Nonlinear parameter estimation through particle swarm optimization publication-title: Chem. Eng. Sci. doi: 10.1016/j.ces.2007.11.024 – volume: 38 start-page: 279 year: 2020 end-page: 296.e9 ident: CR18 article-title: Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.06.005 – volume: 133 start-page: 235 year: 2017 end-page: 248 ident: CR45 article-title: Simulation-based optimization of radiotherapy: Agent-based modeling and reinforcement learning publication-title: Math. Comput. Simul. doi: 10.1016/j.matcom.2016.05.008 – volume: 77 start-page: 6442 year: 2017 end-page: 6452 ident: CR46 article-title: In Silico Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal Cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-2006 – volume: 105 start-page: 1628 year: 2011 end-page: 1634 ident: CR56 article-title: Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments publication-title: Br. J. Cancer doi: 10.1038/bjc.2011.385 – volume: 1516 start-page: 335 year: 2016 end-page: 346 ident: CR42 article-title: Agent-Based Modeling of Cancer Stem Cell Driven Solid Tumor Growth publication-title: Methods Mol. Biol. doi: 10.1007/7651_2016_346 – volume: 38 start-page: 2337 year: 2019 end-page: 2350 ident: CR63 article-title: Androgen Signaling is Essential for Development of Prostate Cancer Initiated From Prostatic Basal Cells publication-title: Oncogene doi: 10.1038/s41388-018-0583-7 – volume: 235 start-page: 116791 year: 2019 ident: CR20 article-title: Cancer-associated fibroblast regulate proliferation and migration of prostate cancer cells through TGF-β signaling pathway publication-title: Life Sci. doi: 10.1016/j.lfs.2019.116791 – volume: 59 start-page: 5002 year: 1999 end-page: 5011 ident: CR12 article-title: Carcinoma-associated Fibroblasts Direct Tumor Progression of Initiated Human Prostatic Epithelium publication-title: Cancer Res. – volume: 56 start-page: 1687 year: 2007 end-page: 1700 ident: CR17 article-title: Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-007-0343-y – volume: 71 start-page: 209 year: 2021 end-page: 249 ident: CR1 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 – volume: 12 start-page: 298 year: 2012 end-page: 306 ident: CR6 article-title: The immune contexture in human tumours: impact on clinical outcome publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3245 – volume: 18 year: 2019 ident: CR55 article-title: Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis publication-title: Mol. Cancer doi: 10.1186/s12943-019-0976-4 – volume: 7 start-page: e47045 year: 2012 ident: CR23 article-title: The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer publication-title: PLoS One doi: 10.1371/journal.pone.0047045 – volume: 25 start-page: R331 year: 2018 end-page: R349 ident: CR22 article-title: Androgen receptor moonlighting in the prostate cancer microenvironment publication-title: Endocr. Rel. Cancer doi: 10.1530/ERC-18-0042 – volume: 86 start-page: 1065 year: 2009 end-page: 1073 ident: CR54 article-title: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation publication-title: J. Leukocyte Biol. doi: 10.1189/jlb.0609385 – volume: 11 start-page: e1004025 year: 2015 ident: CR41 article-title: Evolution and Phenotypic Selection of Cancer Stem Cells publication-title: PLOS Comput. Biol. doi: 10.1371/journal.pcbi.1004025 – volume: 11 start-page: 519383 year: 2020 ident: CR32 article-title: Androgen Receptor Signaling Positively Regulates Monocytic Development publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.519383 – volume: 65 start-page: 1180 year: 2011 end-page: 1192 ident: CR57 article-title: Characterising the castration-resistant prostate cancer population: a systematic review publication-title: Int. J. Clin. Pract. doi: 10.1111/j.1742-1241.2011.02799.x – volume: 11 year: 2020 ident: CR30 article-title: Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion publication-title: Nat. Commun. doi: 10.1038/s41467-020-18313-y – volume: 108 start-page: 19701 year: 2011 end-page: 19706 ident: CR39 article-title: Mathematical modeling of prostate cancer progression in response to androgen ablation therapy publication-title: Proc. Natl Acad. Sci. doi: 10.1073/pnas.1115750108 – volume: 110 start-page: 469 year: 2014 end-page: 478 ident: CR16 article-title: Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.748 – volume: 19 start-page: 1778 year: 2021 end-page: 1791 ident: CR24 article-title: The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-20-0740 – volume: 73 start-page: 5633 year: 2013 end-page: 5646 ident: CR27 article-title: Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-3228 – volume: 9 start-page: 4792 year: 2003 end-page: 4801 ident: CR60 article-title: Reactive Stroma as a Predictor of Biochemical-Free Recurrence in Prostate Cancer publication-title: Clin. Cancer Res. – volume: 39 start-page: 1464 year: 2021 end-page: 1478.e8 ident: CR15 article-title: Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.09.005 – volume: 45 start-page: 831 year: 2021 end-page: 838 ident: CR51 article-title: M2 macrophages contribute to cell proliferation and migration of breast cancer publication-title: Cell Biol. Int. doi: 10.1002/cbin.11528 – volume: 2022 start-page: 8580043 year: 2022 ident: CR52 article-title: The Roles of Tumor-Associated Macrophages in Prostate Cancer publication-title: J. Oncol. doi: 10.1155/2022/8580043 – volume: 24 start-page: 4612 year: 2018 end-page: 4626 ident: CR9 article-title: Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-0461 – volume: 10 start-page: e0122827 year: 2015 ident: CR66 article-title: A comprehensive review of swarm optimization algorithms publication-title: PLoS One doi: 10.1371/journal.pone.0122827 – volume: 3 start-page: 1473 year: 2023 end-page: 1485 ident: CR48 article-title: Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model publication-title: Cancer Res. Commun. doi: 10.1158/2767-9764.CRC-23-0097 – volume: 107 start-page: 1918 year: 2011 end-page: 1922 ident: CR13 article-title: Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer publication-title: BJU Int. doi: 10.1111/j.1464-410X.2010.09804.x – volume: 116 start-page: 1152 year: 2019 end-page: 1161 ident: CR33 article-title: Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth publication-title: Proc. Natl Acad. Sci. doi: 10.1073/pnas.1815735116 – volume: 264 start-page: 517 year: 2010 end-page: 527 ident: CR35 article-title: Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer publication-title: J. Theor. Biol. doi: 10.1016/j.jtbi.2010.02.027 – volume: 2 start-page: 011002 year: 2012 ident: CR36 article-title: A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy publication-title: AIP Adv. doi: 10.1063/1.3697848 – volume: 33 start-page: 300 year: 2023 end-page: 311 ident: CR40 article-title: Agent-based methods facilitate integrative science in cancer publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2022.10.006 – volume: 5 start-page: 569 year: 1999 end-page: 576 ident: CR7 article-title: Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma publication-title: Clin. Cancer Res. – volume: 9 start-page: 016002 year: 2012 ident: CR64 article-title: Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line publication-title: Phys. Biol. doi: 10.1088/1478-3975/9/1/016002 – volume: 5 year: 2005 ident: CR4 article-title: Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival publication-title: Cancer Cell Int. doi: 10.1186/1475-2867-5-8 – volume: 78 start-page: 5155 year: 2018 end-page: 5163 ident: CR47 article-title: High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific In Silico Models of Metastatic Colorectal Cancer. publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-1126 – volume: 18 start-page: 349 year: 2008 end-page: 355 ident: CR21 article-title: Macrophage polarization in tumour progression publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2008.03.004 – volume: 41 start-page: 781 year: 2010 end-page: 793 ident: CR58 article-title: Multifocal prostate cancer: biologic, prognostic, and therapeutic implications publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2010.02.011 – ident: CR65 – volume: 11 start-page: e76284 year: 2022 ident: CR34 article-title: Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes publication-title: eLife doi: 10.7554/eLife.76284 – volume: 12 start-page: 1308 year: 2018 end-page: 1323 ident: CR26 article-title: Loss of androgen receptor signaling in prostate cancer‐associated fibroblasts (CAFs) promotes CCL2‐ and CXCL8‐mediated cancer cell migration publication-title: Mol. Oncol. doi: 10.1002/1878-0261.12327 – volume: 34 start-page: 215 year: 2017 end-page: 240 ident: CR43 article-title: A model of the effects of cancer cell motility and cellular adhesion properties on tumour-immune dynamics publication-title: Math. Med. Biol. – volume: 25 start-page: 276 year: 2004 end-page: 308 ident: CR3 article-title: Androgen receptor in prostate cancer publication-title: Endocr. Rev. doi: 10.1210/er.2002-0032 – volume: 8 start-page: e60562 year: 2013 ident: CR61 article-title: Stromal Response to Prostate Cancer: Nanotechnology-Based Detection of Thioredoxin-Interacting Protein Partners Distinguishes Prostate Cancer Associated Stroma from That of Benign Prostatic Hyperplasia publication-title: PLoS One doi: 10.1371/journal.pone.0060562 – volume: 14 start-page: 4923 year: 2022 ident: CR10 article-title: Spatial Profiling of the Prostate Cancer Tumor Microenvironment Reveals Multiple Differences in Gene Expression and Correlation with Recurrence Risk publication-title: Cancers doi: 10.3390/cancers14194923 – volume: 33 start-page: 2423 year: 2014 end-page: 2431 ident: CR49 article-title: Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression publication-title: Oncogene doi: 10.1038/onc.2013.191 – volume: 175 start-page: 1972 year: 2018 end-page: 1988.e16 ident: CR14 article-title: Organoid Modeling of the Tumor Immune Microenvironment publication-title: Cell doi: 10.1016/j.cell.2018.11.021 – volume: 69 start-page: 799 year: 2009 end-page: 809 ident: CR8 article-title: Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients publication-title: Prostate doi: 10.1002/pros.20927 – volume: 201 start-page: 2923 year: 2018 end-page: 2933 ident: CR31 article-title: Androgen and Androgen Receptor as Enhancers of M2 Macrophage Polarization in Allergic Lung Inflammation publication-title: J. Immunol. doi: 10.4049/jimmunol.1800352 – volume: 20 start-page: 3001 year: 2002 end-page: 3015 ident: CR2 article-title: Molecular biology of the androgen receptor publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2002.10.018 – volume: 10 start-page: 71 year: 2003 end-page: 81 ident: CR53 article-title: Ablation of NK Cell Function During Tumor Growth Favors Type 2-Associated Macrophages, Leading to Suppressed CTL Generation publication-title: J. Immunol. Res. – ident: CR59 – volume: 61 start-page: 423 year: 2001 end-page: 427 ident: CR25 article-title: Altered Expression of Androgen Receptor in the Malignant Epithelium and Adjacent Stroma Is Associated with Early Relapse in Prostate Cancer publication-title: Cancer Res. – volume: 38 start-page: 5339 year: 2019 end-page: 5355 ident: CR19 article-title: Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer publication-title: Oncogene doi: 10.1038/s41388-019-0805-7 – volume: 13 year: 2022 ident: CR11 article-title: Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease publication-title: Nat. Commun. doi: 10.1038/s41467-022-33780-1 – volume: 18 start-page: 593 year: 2008 ident: CR37 article-title: A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer publication-title: J. Nonlinear Sci. doi: 10.1007/s00332-008-9031-0 – volume: 3 start-page: 1 year: 2019 end-page: 8 ident: CR29 article-title: Understanding the Dynamics of T-Cell Activation in Health and Disease Through the Lens of Computational Modeling publication-title: JCO Clin. Cancer Inform. doi: 10.1200/CCI.18.00057 – volume: 11 start-page: 1314 year: 2017 end-page: 1323 ident: CR68 article-title: Parameter Tuning of Complex Systems Modeled in Agent Based Modeling and Simulation publication-title: Int. J. Comput. Inf. Eng. – volume: 38 start-page: 5339 year: 2019 ident: 344_CR19 publication-title: Oncogene doi: 10.1038/s41388-019-0805-7 – volume: 133 start-page: 235 year: 2017 ident: 344_CR45 publication-title: Math. Comput. Simul. doi: 10.1016/j.matcom.2016.05.008 – volume: 201 start-page: 2923 year: 2018 ident: 344_CR31 publication-title: J. Immunol. doi: 10.4049/jimmunol.1800352 – volume: 116 start-page: 1152 year: 2019 ident: 344_CR33 publication-title: Proc. Natl Acad. Sci. doi: 10.1073/pnas.1815735116 – volume: 175 start-page: 1972 year: 2018 ident: 344_CR14 publication-title: Cell doi: 10.1016/j.cell.2018.11.021 – volume: 11 start-page: e76284 year: 2022 ident: 344_CR34 publication-title: eLife doi: 10.7554/eLife.76284 – volume: 18 year: 2019 ident: 344_CR55 publication-title: Mol. Cancer doi: 10.1186/s12943-019-0976-4 – volume: 69 start-page: 799 year: 2009 ident: 344_CR8 publication-title: Prostate doi: 10.1002/pros.20927 – volume: 93 start-page: 641 year: 2017 ident: 344_CR44 publication-title: Simulation doi: 10.1177/0037549717699072 – volume: 13 year: 2022 ident: 344_CR11 publication-title: Nat. Commun. doi: 10.1038/s41467-022-33780-1 – volume: 33 start-page: 300 year: 2023 ident: 344_CR40 publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2022.10.006 – volume: 7 start-page: e47045 year: 2012 ident: 344_CR23 publication-title: PLoS One doi: 10.1371/journal.pone.0047045 – volume: 5 year: 2005 ident: 344_CR4 publication-title: Cancer Cell Int. doi: 10.1186/1475-2867-5-8 – volume: 3 start-page: 1473 year: 2023 ident: 344_CR48 publication-title: Cancer Res. Commun. doi: 10.1158/2767-9764.CRC-23-0097 – volume: 2022 start-page: 8580043 year: 2022 ident: 344_CR52 publication-title: J. Oncol. doi: 10.1155/2022/8580043 – volume: 25 start-page: R331 year: 2018 ident: 344_CR22 publication-title: Endocr. Rel. Cancer doi: 10.1530/ERC-18-0042 – volume: 45 start-page: 831 year: 2021 ident: 344_CR51 publication-title: Cell Biol. Int. doi: 10.1002/cbin.11528 – volume: 18 start-page: 593 year: 2008 ident: 344_CR37 publication-title: J. Nonlinear Sci. doi: 10.1007/s00332-008-9031-0 – volume: 73 start-page: 5633 year: 2013 ident: 344_CR27 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-3228 – volume: 12 start-page: 1665 year: 2006 ident: 344_CR5 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-0067 – volume: 19 start-page: 1778 year: 2021 ident: 344_CR24 publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-20-0740 – volume: 38 start-page: 2337 year: 2019 ident: 344_CR63 publication-title: Oncogene doi: 10.1038/s41388-018-0583-7 – volume: 41 start-page: 781 year: 2010 ident: 344_CR58 publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2010.02.011 – volume: 10 start-page: e0122827 year: 2015 ident: 344_CR66 publication-title: PLoS One doi: 10.1371/journal.pone.0122827 – volume: 12 start-page: 298 year: 2012 ident: 344_CR6 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3245 – volume: 3 start-page: 1 year: 2019 ident: 344_CR29 publication-title: JCO Clin. Cancer Inform. doi: 10.1200/CCI.18.00057 – volume: 11 year: 2020 ident: 344_CR30 publication-title: Nat. Commun. doi: 10.1038/s41467-020-18313-y – volume: 86 start-page: 1065 year: 2009 ident: 344_CR54 publication-title: J. Leukocyte Biol. doi: 10.1189/jlb.0609385 – volume: 7 start-page: e1462431 year: 2018 ident: 344_CR69 publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1462431 – volume: 368 start-page: 5029 year: 2010 ident: 344_CR38 publication-title: Phys. Eng. Sci. – volume: 61 start-page: 423 year: 2001 ident: 344_CR25 publication-title: Cancer Res. – volume: 41 start-page: 267 year: 2014 ident: 344_CR62 publication-title: Semin. Oncol. doi: 10.1053/j.seminoncol.2014.03.004 – volume: 20 start-page: 3001 year: 2002 ident: 344_CR2 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2002.10.018 – volume: 63 start-page: 1542 year: 2008 ident: 344_CR67 publication-title: Chem. Eng. Sci. doi: 10.1016/j.ces.2007.11.024 – volume: 264 start-page: 517 year: 2010 ident: 344_CR35 publication-title: J. Theor. Biol. doi: 10.1016/j.jtbi.2010.02.027 – volume: 235 start-page: 116791 year: 2019 ident: 344_CR20 publication-title: Life Sci. doi: 10.1016/j.lfs.2019.116791 – volume: 11 start-page: e1004025 year: 2015 ident: 344_CR41 publication-title: PLOS Comput. Biol. doi: 10.1371/journal.pcbi.1004025 – volume: 9 start-page: 016002 year: 2012 ident: 344_CR64 publication-title: Phys. Biol. doi: 10.1088/1478-3975/9/1/016002 – volume: 11 start-page: 1314 year: 2017 ident: 344_CR68 publication-title: Int. J. Comput. Inf. Eng. – volume: 56 start-page: 1687 year: 2007 ident: 344_CR17 publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-007-0343-y – volume: 18 start-page: 349 year: 2008 ident: 344_CR21 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2008.03.004 – volume: 12 start-page: 1308 year: 2018 ident: 344_CR26 publication-title: Mol. Oncol. doi: 10.1002/1878-0261.12327 – ident: 344_CR65 – volume: 10 start-page: 71 year: 2003 ident: 344_CR53 publication-title: J. Immunol. Res. doi: 10.1080/10446670310001626580 – ident: 344_CR59 doi: 10.1101/2023.06.06.543873 – volume: 107 start-page: 1918 year: 2011 ident: 344_CR13 publication-title: BJU Int. doi: 10.1111/j.1464-410X.2010.09804.x – volume: 24 start-page: 4612 year: 2018 ident: 344_CR9 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-0461 – volume: 110 start-page: 469 year: 2014 ident: 344_CR16 publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.748 – volume: 105 start-page: 1628 year: 2011 ident: 344_CR56 publication-title: Br. J. Cancer doi: 10.1038/bjc.2011.385 – volume: 108 start-page: 19701 year: 2011 ident: 344_CR39 publication-title: Proc. Natl Acad. Sci. doi: 10.1073/pnas.1115750108 – volume: 33 start-page: 2423 year: 2014 ident: 344_CR49 publication-title: Oncogene doi: 10.1038/onc.2013.191 – volume: 65 start-page: 1180 year: 2011 ident: 344_CR57 publication-title: Int. J. Clin. Pract. doi: 10.1111/j.1742-1241.2011.02799.x – volume: 9 start-page: 4792 year: 2003 ident: 344_CR60 publication-title: Clin. Cancer Res. – volume: 39 start-page: 1464 year: 2021 ident: 344_CR15 publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.09.005 – volume: 77 start-page: 6442 year: 2017 ident: 344_CR46 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-2006 – volume: 38 start-page: 279 year: 2020 ident: 344_CR18 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.06.005 – volume: 17 start-page: 445 year: 2000 ident: 344_CR28 publication-title: Int. J. Oncol. – volume: 2 start-page: 011002 year: 2012 ident: 344_CR36 publication-title: AIP Adv. doi: 10.1063/1.3697848 – volume: 14 start-page: 4923 year: 2022 ident: 344_CR10 publication-title: Cancers doi: 10.3390/cancers14194923 – volume: 5 start-page: 569 year: 1999 ident: 344_CR7 publication-title: Clin. Cancer Res. – volume: 1516 start-page: 335 year: 2016 ident: 344_CR42 publication-title: Methods Mol. Biol. doi: 10.1007/7651_2016_346 – volume: 78 start-page: 5155 year: 2018 ident: 344_CR47 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-1126 – volume: 25 start-page: 276 year: 2004 ident: 344_CR3 publication-title: Endocr. Rev. doi: 10.1210/er.2002-0032 – volume: 8 start-page: e60562 year: 2013 ident: 344_CR61 publication-title: PLoS One doi: 10.1371/journal.pone.0060562 – volume: 71 start-page: 209 year: 2021 ident: 344_CR1 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 – volume: 59 start-page: 5002 year: 1999 ident: 344_CR12 publication-title: Cancer Res. – volume: 34 start-page: 215 year: 2017 ident: 344_CR43 publication-title: Math. Med. Biol. – volume: 11 start-page: 519383 year: 2020 ident: 344_CR32 publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.519383 – volume: 79 start-page: 363 year: 2019 ident: 344_CR50 publication-title: The Prostate doi: 10.1002/pros.23742 |
SSID | ssj0001634210 |
Score | 2.2819602 |
Snippet | Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but... Abstract Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients,... |
SourceID | doaj pubmedcentral proquest pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 20 |
SubjectTerms | 631/553 631/67 692/4028 Androgen Antagonists Androgen receptors Androgens Bioinformatics Biomedical and Life Sciences Castration Cell interactions Cell proliferation Computational Biology/Bioinformatics Computer Appl. in Life Sciences Fibroblasts Growth patterns Humans Immunomodulation Immunomodulators Inflammation Life Sciences Macrophages Male Prostate - pathology Prostate cancer Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Receptors, Androgen - metabolism Systems Analysis Systems Biology Tumor cells Tumor Microenvironment Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOilNH06SYsKvbUiq6e1xzQkhEJ7aiA3oZebQGMva-8hP6D_uzOyd7vb56U-WrI8aGaYGWnmG0LeNMaKGBvPQmMDU9Im5vk8s6wiOAvZz21pNvHxk7m4VB-u9NVWqy_MCRvhgceNO44xYeRk60ZEZbP0hicuggLtUI3OBQkUbN5WMFVOV4xUEMxMVTIzaY97sFSYySgUKzB3zOxYogLY_zsv89dkyZ9uTIshOn9EHk4eJD0ZKd8n93L7mNwfe0rePSHfTrBYiqF1SrT0uYFVaNdQ8PToAms8wLukw-q2W9JbzMbbKnWjYOQwpbOnPSZaw1_GeV8gVh-uaURfEltKDD31baI3WFvSwT-wBVi3vMPlF5innfun5PL87PPpBZt6LbCoFR9Y5t4GYRotQgq1CTnNpDYqRat10AF0KfoaGFtDzJYNgrZnUZuoeEJo0TSXz8he27X5BaG15EKkZEXmSeno_TyqyEOYqdhIeCrC1_vu4gREjsR_deVCXFo38soBr1zhlTMVebv5ZjHCcPx19ntk52YmQmiXFyBYbhIs9y_BqsjRWhjcpNe9E-BNIoaiguHXm2HQSLxm8W3uVjgHrzKBEFuR56PsbCiRVuJJm6iI3ZGqHVJ3R9qb64L6zYEwcLZg0XdrAfxB15_34uB_7MUheSCK5ggm-BHZG5ar_BKcsSG8Knr3HR0UMnk priority: 102 providerName: Directory of Open Access Journals – databaseName: HAS SpringerNature Open Access 2022 dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKKyQuiHcDBRmJG1isH3G8xwVRVSvBBSr1ZvmVthJNVpvsoT-A_82Mk2xZKEjkGE-cUWYmM7ZnviHkTa2NCKF2zNfGMyVNZI7PE0sqQLCQ3NzkZhOfv-iTU7U8K8_2iJhqYXLSfoa0zL_pKTvsfQeOBhMRhWIZpY7pO-QAodpBtw8Wi-XX5c3OipYKFjJjhcxMmlse3vFCGaz_tgjzz0TJ305LsxM6fkDuj9EjXQz8PiR7qXlE7g79JK8fkx8LLJRi6JkizT1uYBba1hSiPLrC-g6ILGm_uWrX9Aoz8X4pc6Pg4DCds6MdJlnDWwa6c1in9xc0YByJ7ST6jrom0kusK2nhHdj-q11f4_QrzNFO3RNyevzp28cTNvZZYKFUvGeJO-OFrkvho6-0T3EmS61iMGXpSw92FFwFQq1gvZY0ArYnUemgeERY0TiXT8l-0zbpkNBKciFiNCLxqMrg3DyowL2fqVBLuArCp-9uwwhCjsx_t_kwXBo7yMqCrGyWldUFebt9ZjVAcPyT-gOKc0uJ8Nn5Rrs-t6M62RAiLsdNVYugTJJO88iFV_DLVXWZVEGOJmWwo013VkAkifiJCoZfb4fBGvGIxTWp3SANHmMCI6Ygzwbd2XIijcRdNlEQs6NVO6zujjSXFxnxmwNjEGjBpO8mBbzh6-_f4vn_kb8g90S2EcEEPyL7_XqTXkLI1ftXo439BHF_KUo priority: 102 providerName: Springer Nature |
Title | Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties |
URI | https://link.springer.com/article/10.1038/s41540-024-00344-6 https://www.ncbi.nlm.nih.gov/pubmed/38383542 https://www.proquest.com/docview/2929308744 https://www.proquest.com/docview/2930473448 https://pubmed.ncbi.nlm.nih.gov/PMC10881528 https://doaj.org/article/ccd027487f2c48e3a61d12b40884f5e4 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9swDBa2FgN2Gfaety7QgN02odHDsnIa0qBFEWDFsK1Abob1cFugtbPYOfQH7H-PlJ1k6SuXALYiMyYpUiL5kZDPpTbCubJgtjSWKWk8K_gosKAcOAuhGJnYbOL7iT4-VdNZOusP3Jo-rXK1JsaF2tcOz8j3BdhxRK9T6tv8D8OuURhd7VtoPCa7CF2GUp3Nss0Zi5YKtjR9rcxQmv0G7BXmMwrFItgd01v2KML23-Vr3k6ZvBE3jebo6Dl51vuRdNwx_gV5FKqX5EnXWfL6Ffk7xpIphjbK09jtBmahdUnB36NzrPQAH5O2y6t6Qa8wJ--_gjcKpg4TOxvaYLo1PKUbdwY79vacOvQosbFE29Ci8vQCK0xqeAY2AqsX1zj9HLO1Q_OanB4d_p4cs77jAnOp4i0LvDBW6DIV1ttM2-CHMtXKO5OmNrWgUa7IgL0Z7NyCRuj2IDLtFPcIMOpH8g3ZqeoqvCM0k1wI740I3KvUFcXIKcetHSpXSvgkhK_ee-56OHIk_jKPYXFp8o5XOfAqj7zKdUK-rH8z78A4Hhx9gOxcj0Qg7XihXpzlvV7mznncmJusFE6ZIAvNPRdWweKryjSohOythCHvtbvJN7KYkE_r26CXGGwpqlAvcQwGNIEQk5C3neysKZFG4nmbSIjZkqotUrfvVBfnEfubA2HgcsGkX1cCuKHr_nfx_uG_8YE8FVEnBBN8j-y0i2X4CM5WawdRowZkdzye_prC98HhyY-fcHWiJ4N4gPEPhbMvSQ |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgQXxLspBYwEJ7C6dpzEe0CoPKotfZxaaW8mfqStRJPtJqtqfwB_h9_IjJPssjx66x43jjPJjGfGnplvCHldpEpYW-TMFMowGSvHcj70zEsLzoLPhyo0mzg8Skcn8us4Ga-Rn30tDKZV9joxKGpXWTwj3xZgxxG9TsoPk0uGXaMwutq30GjFYt_Pr2DLVr_f-wz8fSPE7pfjTyPWdRVgNpG8YZ7nyoi0SIRxJkuNd4M4SaWzKklMYkBqbJ7BK2SwO_EpwpN7kaVWcocgmg7Bl0Dl3wLDO8DNXjbOlmc6aSxhC9XV5gxitV2DfcT8SSFZANdj6Yr9C20C_uXb_p2i-UecNpi_3fvkXue30p1W0B6QNV8-JLfbTpbzR-THDpZoMbSJjobuOjALrQoK_iWdYGUJ-LS0mV1UU3qBOYC_FdhRMK2YSFrTGtO74SntuNNpddWcUYseLDayaGqal46eY0VLBc_AxmPVdI7TTzA73NePycmN8OIJWS-r0m8QmsVcCOeU8NzJxOb50ErLjRlIW8Twiwjvv7u2Hfw5Ev9dhzB8rHTLKw280oFXOo3I28U9kxb849rRH5Gdi5EI3B3-qKanutMD2lqHBwEqK4SVysd5yh0XRoKyl0XiZUS2emHQnTap9VL2I_JqcRn0AAZ38tJXMxyDAVQgREXkaSs7C0piFeP5noiIWpGqFVJXr5TnZwFrnANh4OLBpO96AVzS9f9vsXn9a7wkd0bHhwf6YO9o_xm5K8L6EEzwLbLeTGf-OTh6jXkRVhcl3256Of8CeH1mMA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1Jo6gXhB3JcxwEjwBFZrx0ncB4Q2tmpjUE2ISXsL8SXbJJZ0TaqpH8BP8XWc4yQt5bK35TFxnOOcq31uhLzKYyWMyTOmc6WZDJVlGR865qQBY8FlQ-WbTXwex_vH8uNJdLJGfna5MBhW2clEL6htafCMvC9Aj2P1Oin7eRsWcbQ7ej-5ZNhBCj2tXTuNhkQO3fwKtm_Vu4NdwPVrIUZ7Xz_ss7bDADOR5DVzPFNaxHkktNVJrJ0dhFEsrVFRpCMNFGSyBJaTwE7FxViq3IkkNpJbLKhpsRATiP_1BHdFPbK-szc--rI84YlDCRuqNlNnEKp-BdoSoymFZL7UHotXtKFvGvAvS_fvgM0_vLZeGY7ukbutFUu3G7K7T9Zc8YDcavpazh-SH9uYsMVQQ1rqe-3ALLTMKVibdIJ5JmDh0np2UU7pBUYE_pZuR0HRYlhpRSsM9oavNONOp-VVfUYN2rPY1qKuaFZYeo75LSV8A9uQldM5Tj_BWHFXPSLHN4KNx6RXlIXbIDQJuRDWKuG4lZHJsqGRhms9kCYP4QoI7_57atpi6Aj899Q75UOVNrhKAVepx1UaB-TN4p1JUwrk2tE7iM7FSCzj7W-U09O0lQqpMRaPBVSSCyOVC7OYWy60BNEv88jJgGx1xJC2sqVKl5wQkJeLxyAV0NWTFa6c4Rh0pwIgKiBPGtpZQBKqEE_7REDUClWtgLr6pDg_85XHOQAGBh9M-rYjwCVc__8Xm9cv4wW5DaycfjoYHz4ld4RnD8EE3yK9ejpzz8Dqq_Xzlr0o-XbTHP0LSldryw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Agent-based+modeling+of+the+prostate+tumor+microenvironment+uncovers+spatial+tumor+growth+constraints+and+immunomodulatory+properties&rft.jtitle=NPJ+systems+biology+and+applications&rft.au=van+Genderen%2C+Maisa+N+G&rft.au=Kneppers%2C+Jeroen&rft.au=Zaalberg%2C+Anniek&rft.au=Bekers%2C+Elise+M&rft.date=2024-02-21&rft.issn=2056-7189&rft.eissn=2056-7189&rft.volume=10&rft.issue=1&rft.spage=20&rft_id=info:doi/10.1038%2Fs41540-024-00344-6&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-7189&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-7189&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-7189&client=summon |